

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (KL-152) GLENZOCIMAB
 PRONUNCIATION glen zoe' ki mab
 THERAPEUTIC CLAIM Treatment of the acute phase of ischemic stroke

CHEMICAL NAMES

Immunoglobulin G1, anti-(human platelet glycoprotein VI) Fab fragment (humanized monoclonal ACT017 γ 1-chain), disulfide with humanized monoclonal ACT017 κ -chain

Immunoglobulin Fab G1-kappa, anti-[*Homo sapiens* GP6 (glycoprotein VI platelet, glycoprotein VI (platelet), GPVI, platelet glycoprotein VI)], humanized monoclonal antibody; gamma1 heavy chain VH-CH1 humanized (1-227) [VH (*Homo sapiens* IGHV1-46*01 (92.9%) -IGHD) -IGHJ4*01 (93.3%)] [8.8.13] (1-120) -*Homo sapiens* IGHG1*01, G1m17 (CH1 K120 (217) (121-218), hinge 1-9 (219-227)) (121-227)], (223-214')-disulfide with kappa light chain humanized (1'-219') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (80.0%) -IGKJ1*01 (100%)] [11.3.9] (1'-111') -1-mer (112') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'-219')] (Source: WHO pINN list 118)

STRUCTURAL FORMULA

Heavy Chain (X)

QVQLVQSGAE	VKKPGASVKV	SCKASGYTFT	SYNMHWVRQA	PGQGLEWMGG	50
IYPGNGDTSY	NQKFQGRVTM	TRDTSTSTVY	MELSSLRSED	TAVYYCARGT	100
VVDWYFDVW	GQGTLVTVSS	ASTKGPSVFP	LAPSSKSTSG	GTAAALGCLVK	150
DYFPEPVTVS	WNSGALTSKV	HTFPAVLQSS	GLYSLSSVVT	VPSSSLGTQT	200
YICNVNHKPS	NTKVDKKEP	KSCDKTH			227

Light chain X'

DIQMTQSPSS	LSASVGRVT	ITCRSSQSLE	NSNGNTYLNW	YQQKPGKAPK	50'
LLIYRVSNRF	SGVPSRFSGS	GGSTDFTFPI	SSLQPEDIAT	YYCLQLTHVP	100'
WTFGQGTKVE	ITRTVAAPSV	FIFPPSDEQL	KSGTASVVCL	LNNFYPREAK	150'
VQWKVDNALQ	SGNSQESVTE	QDSKDYSTYSL	SSTLTLSKAD	YEKHKVYACE	200'
VTHQGLSSPV	TKSFNRGEC				219'

Disulfide bridges

22-96	23'-93'	139'-199'	147-203	223-219'
-------	---------	-----------	---------	----------

Glycosylation sites (N)

None

MOLECULAR FORMULA C₂₁₂₆H₃₂₉₀N₅₇₄O₆₈₃S₁₅

MOLECULAR WEIGHT 48.29 kDa

TRADEMARK None as yet

SPONSOR Acticor Biotech S.A.

CODE DESIGNATIONS ACT017

CAS REGISTRY NUMBER 2101829-58-5

UNII 58D9BCH900

WHO NUMBER 10956

gbk